Analyst consensus rating
DiaMedica Therapeutics Analyst Rating: Strong Buy
Direct answer
DiaMedica Therapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.50.
Forecast evidence checked November 3, 2026.
Get free DiaMedica Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.29
- Average price target
- $15.50
- High price target
- $25.00
- Low price target
- $11.00
- Low target gap
- +18.4%
- Target upside
- +66.8%
- High target gap
- +169.1%
- Target range width
- 150.7%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for DiaMedica Therapeutics?
DiaMedica Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $15.50.
How far are DiaMedica Therapeutics's low and high targets from the recorded price?
The low target implies +18.4%, while the high target implies +169.1%.
How many analysts are included in DiaMedica Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is DiaMedica Therapeutics's target upside or downside calculated?
The average target of $15.50 is divided by the recorded price of $9.29, then one is subtracted to produce +66.8%. This does not guarantee a future return.
When was DiaMedica Therapeutics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.